Arrowhead Pharmaceuticals (ARWR) Change in Accured Expenses (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Change in Accured Expenses data on file, last reported at -$8.6 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 132.45% year-over-year to -$8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $440000.0 (down 99.14% YoY) and the FY2025 annual result came in at $41.5 million, up 29.21% from the prior year.
• Change in Accured Expenses rose to -$8.6 million in Q1 2026, from -$13.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $33.5 million in Q3 2025 to a low of -$20.1 million in Q1 2023.
• A 5-year average of $3.3 million and a median of -$419000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 1985.05% — and 2025, when it soared 6451.31%.
• Tracing ARWR's Change in Accured Expenses over 5 years: stood at -$7.2 million in 2022, then soared by 105.66% to $408000.0 in 2023, then plunged by 1985.05% to -$7.7 million in 2024, then slumped by 75.54% to -$13.5 million in 2025, then soared by 36.04% to -$8.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$8.6 million (Q1 2026), -$13.5 million (Q4 2025), and $33.5 million (Q3 2025), per Business Quant data.